Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ardelyx Inc ARDX

Healthcare Biotechnology
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

Recent & Breaking News (NDAQ:ARDX)

Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023

GlobeNewswire February 23, 2023

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire February 2, 2023

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

PR Newswire December 29, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire December 23, 2022

Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire December 16, 2022

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

PR Newswire November 22, 2022

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire November 16, 2022

Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire November 16, 2022

National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels

PR Newswire November 4, 2022

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights

PR Newswire November 3, 2022

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

PR Newswire November 3, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire November 2, 2022

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

PR Newswire October 31, 2022

Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022

PR Newswire October 27, 2022

Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting

PR Newswire October 24, 2022

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

PR Newswire October 20, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire September 30, 2022

Ardelyx to Participate in Upcoming Investor Conferences

PR Newswire September 6, 2022

Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PR Newswire August 4, 2022

Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

PR Newswire August 2, 2022